FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to obtaining chimeric antigen receptors (CAR) with a modified signalling CD3 zeta domain and can be used in medicine. The obtained CAR where in the signalling CD3-zeta domain one or two immunoreceptor tyrosine-based activation motifs (ITAM) selected from ITAM1, ITAM2 and ITAM3 are replaced with by a fragment of the amino acid sequence of integrin beta 3 (TIGB3) can be used to create modified T cells targeting tumor antigen used in effective cancer immunotherapy.
EFFECT: effective cancer immunotherapy.
64 cl, 29 dwg, 1 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
CHIMERIC ANTIGEN RECEPTOR | 2018 |
|
RU2770002C2 |
CHIMERIC ANTIGEN RECEPTOR | 2016 |
|
RU2752880C2 |
CHIMERIC ANTIGENE RECEPTOR | 2019 |
|
RU2810092C2 |
CHIMERIC ANTIGEN RECEPTORS | 2015 |
|
RU2745705C2 |
CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | 2014 |
|
RU2727447C2 |
CHIMERIC ANTIGEN RECEPTORS M971 | 2018 |
|
RU2770411C1 |
CHIMERIC ANTIGENIC RECEPTORS TO BCMA | 2015 |
|
RU2747457C2 |
CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
T- CELLS WITH COSTIMULATING CHIMERIC ANTIGEN RECEPTOR TARGETING IL13Rα2 | 2015 |
|
RU2749922C2 |
RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
Authors
Dates
2021-02-01—Published
2019-03-13—Filed